NeOnc Technologies Holdings, Inc. has signed a non-binding Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH) to collaborate on advancing research and clinical capabilities for oncology and central nervous system (CNS) therapeutics in the Emirate of Abu Dhabi.
Key Details
- Agreement Parties: NeOnc Technologies and the Department of Health – Abu Dhabi (DoH).
- Scope of Collaboration: The partnership aims to facilitate the exchange of scientific knowledge, advance clinical research for CNS tumors, provide specialist training, and explore the potential establishment of a regional presence for NeOnc in Abu Dhabi.
- Terms: The MoU is non-binding and will remain in effect for two years. This agreement builds on NeOnc's existing activity in the region, where its investigational drug NEO100 has received Investigational New Drug (IND) status.